Immutep has narrowed eftilagimod alfa’s potential registration pathway to PD-L1-negative head and neck cancer and neoadjuvant soft tissue sarcoma after identifying product differences between manufacturing scales used in earlier studies and TACTI-004. A new 200 L manufacturing run is planned, but replacement trials are not targeted to start until the second half of 2027 and remain subject to regulatory, funding and partnering decisions.
- Potential manufacturing differences identified between 200 L and 2,000 L efti batches
- Future focus narrowed to PD-L1-negative HNSCC and neoadjuvant soft tissue sarcoma
- New 200 L manufacturing run contracted
- Replacement trials targeted for the second half of 2027, subject to multiple conditions
- Root cause analysis remains incomplete
Manufacturing Difference Emerges After TACTI-004
Immutep Limited (ASX:IMM; NASDAQ:IMMP) is attempting to salvage its lead immunotherapy programme after identifying structural differences between eftilagimod alfa used in the discontinued TACTI-004 study and product used in earlier successful trials. The company said the differences include a subtle variation in N-glycan structure and may be relevant to the markedly different immune activation profile and unexpected clinical outcome observed in TACTI-004.
That is not yet a confirmed explanation for the trial result. Immutep’s root cause analysis is still underway, and the company describes the manufacturing differences as “potentially relevant”. It said the analysis to date has not found clinical or trial-execution factors that could explain the outcome, including protocol shortcomings, material treatment-arm imbalance, safety findings or invalid randomisation.
New 200 L Batch Planned
The company has contracted a new 200 L manufacturing run of efti. Ten GMP batches made at that scale were previously used in Phase I and Phase II studies, including TACTImel, TACTI-002 and INSIGHT-003. TACTI-004, by contrast, used efti manufactured exclusively at the larger 2,000 L scale.
The practical test will be whether the new material can support a credible clinical and regulatory restart. Immutep has not said that the 200 L product is definitively equivalent to the product used in every earlier study, nor has it completed the investigation into smaller batch differences. That leaves product comparability as a central issue before the next trials can carry much weight.
Efti Strategy Narrows to Two Indications
Immutep now intends to concentrate registration-directed development on head and neck squamous cell carcinoma in patients with a Combined Positive Score below 1, and on neoadjuvant treatment of soft tissue sarcoma. The company points to mature overall survival data and limited approved options in the selected HNSCC population, while its soft tissue sarcoma plan rests on positive Phase II data and achievement of the primary endpoint.
The regulatory positioning is more favourable in these two areas than across a broad tumour-type programme. Efti has Fast Track designation for HNSCC and received FDA Orphan Drug Designation for soft tissue sarcoma in April 2026. Immutep said its interactions with the FDA have been constructive, although those designations do not guarantee approval or determine the final design of a registrational study.
Trial Restart Slips Into a Conditional 2027 Window
Preparations for new clinical trials have begun, with study starts targeted for the second half of calendar 2027. That timetable is explicitly conditional on final trial design, further regulatory discussions, manufacturing timelines, partnering and available resources. Immutep’s licensing partner, Dr. Reddy’s Laboratories, has been consulted and supports the proposed approach, while preliminary discussions with other parties are also underway.
The reset therefore offers a path forward rather than an immediate clinical catalyst. The outstanding root cause analysis, successful production of new material and ability to secure the resources for two focused programmes will determine whether the proposed 2027 window becomes a firm development plan. Meanwhile, Immutep said its IMP761 anti-LAG-3 programme for autoimmune disease continues under previously disclosed plans.
Bottom Line?
Immutep has defined a narrower route back into clinical development, but the case now depends on proving that the manufacturing reset is meaningful and financing a trial programme that may not begin until late 2027.
Questions in the middle?
- Will the completed root cause analysis confirm that manufacturing differences contributed to TACTI-004’s outcome?
- Can the new 200 L product demonstrate sufficient comparability to support FDA-agreed trial designs?
- Will Immutep secure the partnering and financial resources needed to start both proposed programmes in the second half of 2027?